{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:17:11Z","timestamp":1776212231961,"version":"3.50.1"},"reference-count":20,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,4,4]]},"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p>SARS-CoV-2 preferentially targets the human\u2019s lungs, but it can affect multiple organ systems. We report a case of cardiorenal syndrome in a 37-year-old man who had symptoms of fever, myalgia and cough. He tested positive for COVID-19 and presented 5\u2009days later with acute heart failure. Work up was done including echocardiography showing reduced ejection fraction. Later in the hospital course he developed acute renal failure and was treated with intermittent renal replacement therapy. No other definite cause of cardiorenal complications was identified during the course of the disease. A possible link with COVID-19 was considered with underlying mechanisms still needed to be explored. This case highlights the potential of SARS-CoV-2 affecting heart and kidneys. The disease not only involves the organs directly but can exacerbate the underlying comorbid illness.<\/jats:p>","DOI":"10.1136\/bcr-2021-241914","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T10:49:03Z","timestamp":1619174943000},"page":"e241914","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiorenal syndrome in COVID-19"],"prefix":"10.1136","volume":"14","author":[{"given":"Uzair Akbar","family":"Ali","sequence":"first","affiliation":[{"name":"Medicine, Mayo General Hospital, Castlebar, Ireland"},{"name":"Medicine, University Hospital Waterford, Waterford, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sajjad","family":"Sadiq","sequence":"additional","affiliation":[{"name":"Endocrinology, Mayo University Hospital, Castlebar, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Jawad","family":"Yunus","sequence":"additional","affiliation":[{"name":"Medicine, Mayo University Hospital, Castlebar, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"2025082712213281000_14.4.e241914.1","doi-asserted-by":"publisher","DOI":"10.1016\/SO140-6736(20)30566-3"},{"key":"2025082712213281000_14.4.e241914.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0360-5"},{"key":"2025082712213281000_14.4.e241914.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.031"},{"key":"2025082712213281000_14.4.e241914.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"2025082712213281000_14.4.e241914.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.03.005"},{"key":"2025082712213281000_14.4.e241914.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"2025082712213281000_14.4.e241914.7","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American heart association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2025082712213281000_14.4.e241914.8","first-page":"219","article-title":"[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]","volume":"43","author":"Sun","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"2025082712213281000_14.4.e241914.9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0310057X1504300507","article-title":"Factors associated with vancomycin nephrotoxicity in the critically ill","volume":"43","author":"Hanrahan","year":"2015","journal-title":"Anaesth Intensive Care"},{"key":"2025082712213281000_14.4.e241914.10","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-020-00075-z"},{"key":"2025082712213281000_14.4.e241914.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.031"},{"key":"2025082712213281000_14.4.e241914.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.006631"},{"key":"2025082712213281000_14.4.e241914.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4326"},{"key":"2025082712213281000_14.4.e241914.14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025082712213281000_14.4.e241914.15","first-page":"291","article-title":"A brand-new cardiorenal syndrome in the COVID-19 setting","volume":"13","author":"Apetrii","year":"2020","journal-title":"Clin Kidney J"},{"key":"2025082712213281000_14.4.e241914.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67130.x"},{"key":"2025082712213281000_14.4.e241914.17","unstructured":"European Society of Cardiology . Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. Available: https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang"},{"key":"2025082712213281000_14.4.e241914.18","unstructured":"American College of Cardiology . HFSA\/ACC\/AHA statement addresses concerns re: using RaaS antagonists in COVID-19. Available: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19"},{"key":"2025082712213281000_14.4.e241914.19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"7","author":"Grover","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025082712213281000_14.4.e241914.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.05.002"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-241914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:21:39Z","timestamp":1756322499000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-241914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,23]]},"published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1136\/bcr-2021-241914"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-241914","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}